Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Bruno Coudert, Jean‐Yves Pierga, Marie‐Ange Mouret‐Reynier, K. Kerrou, Jean-­Marc Ferrero, Thierry Petit, Pierre Kerbrat, Pierre‐François Dupré, Thomas Bachelot, Philippe Gabelle,

The Lancet Oncology · 2014 · 142 citations · 26 references

Concepts

References

26